SynthesisBMC anesthesiology2025
Soluble urokinase plasminogen activator receptor and perioperative complications: a systematic review.
Synthesis in BMC anesthesiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBetter informative predictive tools are required to improve risk-stratification in patients undergoing surgery. Soluble urokinase-type plasminogen activator receptor (suPAR) has the potential to predict postoperative complications. The primary objective of this systematic review was to evaluate the association between suPAR measured around the time of surgery and perioperative complications.
methodsWe systematically reviewed studies indexed in Embase or PubMed from inception up to October 8, 2024. We included studies evaluating the association between suPAR measured around surgery and perioperative complications captured up to 90 days after surgery. We excluded case reports, reviews, editorials, studies with non-human participants, and clinical practice guidelines. We used the Quality in Prognostic Studies tool to assess the risk of bias, and Grading of Recommendations Assessment, Development and Evaluation to ascertain the certainty in the inference for reported associations.
resultsEighteen of the 19 included studies provided evaluable data from 6410 patients on the association between suPAR and perioperative outcomes. There was moderate certainty that suPAR associates with acute kidney injury, low certainty of association with mortality, very low certainty of association with composites of multiple complications, resource utilization outcomes, and infectious complications. However, we were highly uncertain about the magnitude of association because studies were heterogeneous, poorly reported, mostly retrospective, and too small to provide robust estimates.
conclusionsWe conclude that serum or plasma concentrations of suPAR measured around surgery is likely associated with perioperative complications, especially acute kidney injury. The magnitude of these associations and the clinical value of suPAR should now be compared to other clinical information and prognostic biomarkers in biobanks of large prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.